Safety and Efficacy of Gadobutrol for Contrast-enhanced Magnetic Resonance Imaging of the Central Nervous System: Results from a Multicenter, Double-blind, Randomized, Comparator Study | Zendy

Juan Escribano Gutiérrez | Zendy; Martin Rosenberg | Zendy; J. Seemann | Zendy; Josy Breuer | Zendy; Daniel Haverstock | Zendy; Jacob Agris | Zendy; Thomas Balzer | Zendy; Nicoletta Anzalone | Zendy

Open Access

Safety and Efficacy of Gadobutrol for Contrast-enhanced Magnetic Resonance Imaging of the Central Nervous System: Results from a Multicenter, Double-blind, Randomized, Comparator Study

Author(s) -

Juan Escribano Gutiérrez,

Martin Rosenberg,

J. Seemann,

Josy Breuer,

Daniel Haverstock,

Jacob Agris,

Thomas Balzer,

Nicoletta Anzalone

Publication year - 2015

Publication title -

magnetic resonance insights

Language(s) - English

Resource type - Journals

ISSN - 1178-623X

DOI - 10.4137/mri.s19794

Subject(s) - gadobutrol , medicine , magnetic resonance imaging , lesion , radiology , nuclear medicine , gadolinium , contrast (vision) , pathology , chemistry , organic chemistry , artificial intelligence , computer science

Contrast-enhanced magnetic resonance imaging (MRI) of the central nervous system (CNS) with gadolinium-based contrast agents (GBCAs) is standard of care for CNS imaging and diagnosis because of the visualization of lesions that cause blood-brain barrier breakdown. Gadobutrol is a macrocyclic GBCA with high concentration and high relaxivity. The objective of this study was to compare the safety and efficacy of gadobutrol 1.0 M vs unenhanced imaging and vs the approved macrocyclic agent gadoteridol 0.5 M at a dose of 0.1 mmol/kg bodyweight.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research